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West-Nile virus (WNV) is an arbovirus usually transmitted to humans via a mosquito 
vector. Infections commonly result in febrile symptoms while rare severe neuroinvasive 
cases may result in encephalitis or meningitis. Studies have shown that WNV infection 
efficiency is enhanced by expression of DC-SIGNR on target cells, which normally do not 
express DC-SIGNR. To investigate WNV tropism, we established 293T kidney epithelial cell 
lines that stably express vector, DC-SIGNR and mutants of DC-SIGNR that lack the entire 
carbohydrate-recognition domain (CRD) or lack the C-terminal half of the CRD. We 
demonstrate successful surface expression of DC-SIGNR and its mutants from stably-
transfected 293T cells, but not vector-transfected 293T cells. Further, we show that 
monoclonal antibody 120604 which binds specifically to the DC-SIGNR CRD binds to DC-
SIGNR expressing 293T cells, but not to vector nor any of the DC-SIGNR mutants 
expressing cells. Virus replicon particles (VRPs), replication-incompetent viral particles 
containing necessary structural proteins for infection and a viral plasmid including a GFP 
reporter are used to safely and conveniently study viral entry. Entry assays using WNV 
(NY99) VRPs as well as a variant of WNV (NY99) which contains the beta-lactamase 
enzyme show significant entry into DC-SIGNR expressing cell lines, but not in controls that 
do not express DC-SIGNR. Additionally, we show that WNV VRPs do not enter DC-SIGNR 
expressing cells that lack the CRD or the C-terminal half of the CRD suggesting that the C-
terminal half of the CRD is required for successful entry of WNV via DC-SIGNR. Future 
experiments may be able to shed light on which amino acids are required for entry.
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Since its migration to New York in 1999, a strain of West-Nile Virus (WNV) that primarily 
used a bird host and mosquito vector transmission cycle has swept across the western 
hemisphere into Central and South America (1). Human WNV infection may lead to West 
Nile fever, associated with symptoms that persist past 30 days in >60% of cases (1,2). In 
addition, it has been estimated that ≈ 1 in 50 infected patients ≥65 years develop 
encephalitis, meningitis, and paralysis (1, 3). Since, presently, there exist no accepted 
human vaccine, vector preventive measures serve as the primary avenue for combating 
primary infection. Current treatments are mostly supportive (1).
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin Related 
protein (DC-SIGNR) on lung, lymph, and liver endothelia when expressed on a cell line, 
enhanced WNV infection (4) as well as related Flaviviruses Japanese encephalitis virus(5) 
and dengue virus(6). Davis (2006) proposed that N-linked high-mannose oligosaccharides 
primarily on WNV transmembrane protein E have multivalent interactions with the 
carbohydrate recognition domain (CRD) of DC-SIGNR as both anti-CRD antibodies and E 
protein gene knockout reduced infection to levels comparable to control cell lines. 
Further research will identify which amino acids are important for DC-SIGNR-dependent 
WNV infection. DC-SIGN, a related molecule of DC-SIGNR, enhances Flavivirus entry and 
the C-Terminus half of its CRD is primarily responsible for this enhancement (5, 6, 7). 
Although similar, the CRD of DC-SIGN and DC-SIGNR have different ligand molecular 
interactions (7). The purpose of this study is to test whether WNV entry requires the C-
terminal half of the CRD of DC-SIGNR. 
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Surface expression of DC-SIGNR and its mutants






How Does the Virus
Determine its Target?
Structural Components of WNV Virion 
Figure 1. The WNV virion attachment E protein in part determines the tropism of the virus 
by attaching to target cell surface receptors. 
Virus Replicon Particle (VRP) System
Figure 2. Lab produced VRPs are used to safely test 
viral infection. Transfection of two plasmids into HEK-
293T cells leads to the production of WNV VRPs. One 
plasmid expresses the structural membrane, capsid, 
and attachment proteins; PrM, C, and E, respectively. 
While the other plasmid contains a green fluorescent 
protein (GFP) expressed from within a mutated viral 
genome. The structural proteins and GFP containing 
genome assemble to create a non-replicating infectious 
WNV virions. 
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Figure 3. To generate stable expressing DC-SIGNR from 
normally non-expressing HEK-293T cells, the open 
reading frames of DC-SIGNR7 was subcloned into SBP-
mini vector. The SBP-mini vector co-expresses a 
streptavidin-binding mini protein on the cell surface as 
well as hygromycin resistance which was used to select 
out stable cells. Mutations were made to DC-SIGNR7. 
The CRD-1 mutation removed the carbohydrate 
recognition domain and the CRD-2 mutation removed 
half of the domain. These mutants were also used to 






Figure 5. WNV uses the E 
attachment protein to bind to 
a target cell. If the virus gains 
entry into the cell, it releases 
its viral genome into the 
cytoplasm of the target cell. 
GFP is expressed from the 


























Figure 4. DC-SIGNR expression on 293T 
cells. All cells (293T expressing nothing, 
DC-SIGNR, 293T cells expressing DC-
SIGNR CRD1 and 293T cells expressing 
DC-SIGNR CRD2) were stained with anti-
DC-SIGNR monoclonal antibody, 
polyclonal anti-DC-SIGNR antibody and 
finally a monoclonal antibody that stains 
only the CRD in DC-SIGNR. The light 
colored histogram represents stained 
293T cells expressing nothing.
Assaying for WNV PRP Infection 
Generating DC-SIGNR expressing cells with mutations
These results show that WNV VRPs infect 293T DC-SIGNR expressing cells. Eliminating the 
CRD or the C-terminal portion of the CRD ablates efficient entry into the 293T cells. We 
also show that eliminating the CRD from DC-SIGNR does not prevent the mutant’s cell 
surface expression (Figure 4) and therefore the lack of entry by the WNV VRPs is not due 
to lack of cell surface expression of the protein. Altogether, these results demonstrate 
that the CRD is critical for viral entry and suggest that the virus may specifically bind to 
DC-SIGNR via the C-terminal portion of the CRD. Further experiments will be performed 
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Figure 6. WNV entry requires the C-terminal half of the CRD of DC-SIGNR. 293T, 293T 
expressing DC-SIGNR, DC-SIGNR CRD1 (DCRD) and DC-SIGNR CRD (DCRD2) were plated 
in 96 well plates and infected in triplicate with control, WNV (NY99) containing beta-
lactamase and WNV (NY99) for three days. Green fluorescent foci were manually 
counted from each of the three infection wells and graphed above.
